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Activated T cells must mediate effector responses
sufficiently to clear pathogens while avoiding
excessive tissue damage. Here we have combined
dynamic intravital microscopy with ex vivo assess-
ments of T cell cytokine responses to generate
a detailed spatiotemporal picture of CD4+ T cell
effector regulation in the skin. In response to anti-
gen, effector T cells arrested transiently on anti-
gen-presenting cells, briefly producing cytokine
and then resuming migration. Antigen recognition
led to upregulation of the programmed death-1
(PD-1) glycoprotein by T cells and blocking its
canonical ligand, programmed death-ligand 1 (PD-
L1), lengthened the duration of migration arrest
and cytokine production, showing that PD-1 inter-
action with PD-L1 is a major negative feedback
regulator of antigen responsiveness. We speculate
that the immune system employs T cell recruitment,
transient activation, and rapid desensitization to
allow the T cell response to rapidly adjust to changes
in antigen presentation and minimize collateral injury
to the host.
INTRODUCTION
Effector T cells develop from naive T cell precursors in secondary
lymphoid organs upon encountering processed antigen (pMHC
ligands) on antigen-presenting cells (APCs). After activation,
clonal expansion, and differentiation, the T cells acquire the
capacity to produce distinct sets of effector cytokines and,
through the expression of specific tissue-homing receptors, to
access sites of infection or cellular damage via locally inflamed
endothelium (Campbell and Butcher, 2002; Mora et al., 2003)
where they play a crucial role in control of microbial infections
and tumors and are major contributors to tissue-specific auto-
immunity (Swain et al., 2012; Zhu et al., 2010).Once effector T cells enter inflamed tissue and recognize their
specific antigen on tissue-resident APCs, they undergo reactiva-
tion, producing effector cytokines that can contribute to host
defense by enhancing antimicrobial responses. Local chemo-
kine production by these activated T cells or evoked from neigh-
boring cells can promote further recruitment of immune effectors
(Islam and Luster, 2012; Sadik and Luster, 2012). Although these
various cells and mediators are crucial to host defense, many
of the molecules involved can cause substantial damage to
host tissue. Thus, the quality, magnitude, and duration of effector
T cell activity in a tissue site must be carefully regulated to
provide a useful balance between adequate host protection
and acceptable collateral organ damage (Germain et al., 2012;
Sancho et al., 2002; Segel and Bar-Or, 1999).
Until recently, analysis of T cell effector activity, especially in
peripheral tissues, was mainly indirect. Studies of gene-targeted
animals have helped identify specific cytokines involved in pro-
tection against certain pathogens and flow cytometry and
ELISA-based methods have revealed the relationship between
cell phenotype and the capacity to produce these effector
molecules, most often after ex vivo restimulation (Hafalla et al.,
2012; Wilson et al., 2009). A more limited number of studies
have examined cytokine production by T cells without such re-
stimulation (Reinhardt et al., 2003). Static in vivo imaging with
staining for both cell phenotypic markers and cytokines has
also contributed to our understanding of the location and magni-
tude of effector T cell activity in tissues (Egen et al., 2011).
Although this prior work has provided important insights about
effector T cells and their behavior in antigen-rich settings, it lacks
an understanding of the spatiotemporal dynamics of this limb of
the immune system, and particularly the time evolution of the re-
lationships among antigen recognition, cytokine production, and
cell movement. The application of 2-photon (2P) microscopy to
intravital imaging of immune cells has provided a key tool for
such analysis. Initially applied to the behavior of naive T cells in
secondary lymphoid tissues (Bousso and Robey, 2003; Mempel
et al., 2004; Miller et al., 2002; Stoll et al., 2002), this method has
more recently been used to analyze effector T cells in various pe-
ripheral sites (Bartholoma¨us et al., 2009; Beattie et al., 2010;
Egen et al., 2008, 2011; Fife et al., 2009; Filipe-Santos et al.,
2009; Kawakami et al., 2005; Kim et al., 2009; Matheu et al.,Immunity 40, 235–247, February 20, 2014 ª2014 Elsevier Inc. 235
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observation is the rapid movement of activated T cells within
dense tissue and their migration arrest when contacting cells
presenting antigen of suitable quality and quantity. In our studies
involving a BCG-induced liver granuloma model (Egen et al.,
2008, 2011), we reported the close relationship between motility
state and effector function, with the fraction of antigen-specific
cells showing antigen-induced arrest of migration correlating
with the fraction producing interferon-gamma (IFN-g). However,
these and other investigations have not adequately explored the
evolution of the effector response over longer time intervals for
two major reasons: first, the lack of a method for narrowly
defining the moment of initial antigen contact in the tissue so
that the kinetics of the cytokine response can be linked to the
onset of antigen-induced signaling, and second, the inability to
image long enough to observe the temporal arc of the functional
response induced by such antigen stimulation.Without this infor-
mation, critical questions about effector cell behavior such as
what fraction of antigen-specific cells participate in a response,
whether actively migrating cells are high-rate cytokine pro-
ducers, and the mechanisms controlling eventual T cell disen-
gagement from antigen-specific contacts with APCs all remain
unanswered.
To address these issues, we have combined 2P intravital
microscopy with more traditional cellular analytical methods to
examine the spatiotemporal behavior of CD4+ effector T cells
in a skin delayed-type hypersensitivity (DTH) model. Two key
elements of the study were the use of a method that synchro-
nizes the onset of antigen presentation to T cells within an
inflamed tissue site and the extension of the imaging analysis
to a period of up to 10 hr. With these methods, we found that
effector T cells exhibited reduced velocity and high IFN-g pro-
duction immediately after TCR engagement but gradually recov-
ered motility and ceased effector activity over several hours
through a process that was independent of marked decline in
antigen presentation at the inflamed site. During this period,
programmed death-1 (PD-1) expression on effector T cells
increased and blockade of PD-1 activity by an anti-programmed
death-ligand 1 (PD-L1) antibody delayed the recovery of motility
and prolonged the duration of cytokine secretion. These results
indicate that effector T cells undergo rapid tuning of their
sensitivity to antigenic stimulation, in part through T cell recep-
tor (TCR)-dependent negative feedback control afforded by
increased PD-1 expression on T cells. We propose that this
mechanism constrains tissue damage by adapting the magni-
tude of the effector response to the ambient amounts of antigen
present within the inflamed site. These findings suggest a critical
role for central memory cells in generating a continuous source
of new ‘‘virgin’’ effectors, which, upon sequential immigration
into the inflamed site, can sense dynamic fluctuations in antigen
display and generate a proportional effector response.
RESULTS
Both Antigen-Induced Signaling and Tissue Anatomy
Regulate Motility of Effector T Cells in Skin
To explore the dynamic behavior and functionality of effector
T cells in a peripheral inflamed tissue in which we could control
the display of cognate antigen and conduct long-term dynamic236 Immunity 40, 235–247, February 20, 2014 ª2014 Elsevier Inc.in situ imaging, we developed a DTH model in which an adop-
tively transferred antigen-specific population of CD4+ T cells
could be observed in the skin (Figure 1A; Kearney et al., 1994).
Naive TCR transgenic OT-II-Rag-eGFP T cells (OT-II T cells)
were transferred into syngeneic, albino recipient mice, to avoid
tissue damage resulting from absorption of laser excitation
by melanin granules (Masters et al., 2004). These animals were
then immunized with complete Freund’s adjuvant (CFA) contain-
ing keyhole limpet hemocyanin (KLH) and the OT-II TCR-specific
peptide ovalbumin 323-329 (OVA323). Seven days later, the ear
skin was challengedwith an intradermal injection of either KLH or
KLH plus ovalbumin protein (OVA). Immunization and challenge
with KLH evoked a DTH response that led to robust ear swelling
24–48 hr later. Mice with primed OT-II T cells that were rechal-
lenged with KLH+OVA developed only a marginally increased
ear swelling response as compared to those rechallenged with
KLH alone, suggesting that the majority of inflammation is driven
by the response to KLH (Figure S1 available online). The number
of effector OT-II T cells recruited into the inflamed ear at 12 and
60 hr after the challenge was not substantially influenced by
presence of specific antigen at these assay times (Figures 1B
and 1C), revealing that activated effector T cells were recruited
to and retained in inflammatory skin lesions with limited depen-
dence on their antigen specificity, consistent with our previous
report (Egen et al., 2011). This homing characteristic allowed
us to compare the behavior of effector OT-II T cells in KLH-chal-
lenged skin versus KLH+OVA-challenged skin in the same ani-
mal and state of immune response, with the only major variable
being the local presence or absence of specific antigen.
With this system, we first characterized the localization and
migration of OT-II T cells in inflamed skin in the absence of
cognate antigen. Immunofluorescence analysis of skin sections
showed a large number of recruited OT-II T cells in the dermis
surrounded by a rich network of major histocompatibility com-
plex (MHC) class II+ cells, representing potential APCs (Fig-
ure 1D). In these fixed tissue sections we also observed smaller
numbers of OT-II T cells in an epidermal compartment. We
utilized intravital imaging to investigate the dynamic behavior
of the dermal and epidermal OT-II T cell populations, performing
the study in recipientmice that constitutively express dsRed in all
cell types (Ubi-dsRed) so as to visualize the surrounding cellular
environment. These studies revealed that the effector T cells
were relatively free to move throughout the inflamed dermal
environment with its looser mass of connective tissue and cells,
whereas epidermal T cells appeared highly constrained by
their surroundings, showing substantial shape changes as they
squeezed through small openings between tightly adherent
keratinocytes (Figure 1E and Movie S1). As a consequence,
the mean velocity of T cells in the epidermis was substantially
reduced compared to T cells migrating in the dermis (Figure 1F),
consistent with previously reports (Ariotti et al., 2012; Chodaczek
et al., 2012; Gebhardt et al., 2011). These findings emphasize
the critical importance of imaging tissue structure along with
immune cells of interest in interpreting data on migration
dynamics control, and provide insight relevant to effector cell
clearance of epidermal infections. Given the limited motility of
OT-II T cells in the epidermis and our interest in relatingmigratory
dynamics to effector function, we focused on examination of
dermal T cell populations for the remainder of our study.
Figure 1. Characterization of Antigen-Dependent and -Independent Effector T Cell Behavior in Inflamed Skin
(A) Schematic illustration of DTH induction.
(B and C) Representative histograms (B) and quantification (C) of CD4+eGFP+ OT-II T cells from inflamed skin. Ear skin was collected at the indicated time point
and cell composition was analyzed by flow cytometry after tissue disruption. Graph shows the percent of CD4+ cells that are eGFP+;mean ± SD from at least three
mice per group.
(D) Immunofluorescence staining of an inflamed ear section containing OT-II eGFP+ cells during a DTH response. 48 hr after KLH challenge, ear skin was fixed,
sectioned, and stained with DAPI to identify nuclei and an anti-MHC-II Ab. Epidermis (Epi), dermis (Derm), and cartilage (Cart) regions of the ear are indicated.
Note: the side of the ear receiving an intradermal injection of antigen shows the most inflammation and dermal swelling. See also Figure S1.
(E) Representative picture of OT-II T cells in epidermis (top) and dermis (bottom). See also Movie S1.
(F) Comparison of OT-II T cell mean velocity in dermis and epidermis. Each symbol represents an individual cell. Horizontal lines indicate median value of the
population.
(G) Quantification of mean velocity for dermal OT-II T cells in the presence and absence of cognate antigen. Each symbol represents an individual cell. Horizontal
lines indicate median value of the population. p values, unpaired Student’s t test. All data are representative of three or more independent experiments.
Scale bars represent 50 mm. See also Movie S2.
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T cell migration in the inflamed dermis. Previous studies have
demonstrated that effector T cells arrest migration when they
contact a high potency antigen available at adequate density
on tissue APCs (Bartholoma¨us et al., 2009; Beattie et al., 2010;
Egen et al., 2011; Fife et al., 2009; Filipe-Santos et al., 2009;
Kawakami et al., 2005; Kim et al., 2009; Matheu et al., 2008;
Schaeffer et al., 2009; Wilson et al., 2009). In agreement with
these previous results and the abundance of potential APCs in
the dermis, at 12 hr and 24 hr after challenge with KLH+OVA,
OT-II T cells in the dermis had a substantially lowermean velocity
than did OT-II T cells in the ear given only KLH (Figure 1G and
Movie S2). In the absence of cognate antigen recognition (KLH
challenge only), we observed a change in OT-II cell velocity as
the DTH response progressed. Cell velocity increased slightly
from 12 to 24 hr after KLH challenge but then decreased at
later time points, presumably because of the changing inflam-
matory environment. By 48 hr after the challenge, OT-II T cells
in KLH+OVA-challenged ears had regained motility close to
that of OT-II T cells in the KLH-challenged ear.
Temporal Synchronization of Antigen Presentation
Reveals that Effector T Cell Motility and Cytokine
Production Are Anticorrelated
Our observations demonstrating that at an inflamed site in the
presence of antigen, effector OT-II T cell arrest their migration
early in the response but then display heterogeneity in their
motility as the response ensues, led us to investigate the process
bywhich T cells engagewith APCs, generate effector responses,
and then disengage from APC contact, resuming migration. To
generate a synchronized population of effector T cells in which
the moment of antigen recognition is known within a narrow win-
dow, coordinated throughout the population, and observable
during the imaging session, we developed a modified DTH sys-
tem (Figure 2A). Mice were immunized with KLH+OVA323 in CFA
after transfer of naive OT-II T cells and then challenged in the ear
with KLH alone 7 days later to recruit OT-II effector T cells in
the absence of cognate antigen. To synchronously induce and
monitor activation of these T cells, OVA323 peptide was injected
i.v. and OT-II T cell motility changes were observed by intravital
microscopy (Egen et al., 2011; Waite et al., 2011). Before antigen
injection or after injection of an irrelevant peptide antigen, OT-II
T cells moved rapidly with a mean velocity of 5 mm/min).
Within 1 min of OVA323 injection, antigen-specific T cells
showed migration arrest, with higher doses of injected peptide
leading to greater declines in the mean velocity (Figure 2B and
Movie S3), due primarily to more T cells arresting completely
as the antigen dose increased (Figure S2). To determine how
these motility changes correlated with T cell effector activity,
we examined the appearance of intracellular cytokine (IFN-g)
beginning at 2 hr after peptide administration, by a previously
described system in which T cells are analyzed directly
ex vivo, in the absence of restimulation (Egen et al., 2011). The
fraction of OT-II T cells producing IFN-g increased in parallel
with the change in the fraction of arrested cells (Figures 2C
and 2D), in accord with our previous findings (Egen et al., 2011).
Over the course of these acute peptide administration studies,
we found that the antigen-arrested T cells began to regain
motility several hours later (Figure 2B). To extend these findings,238 Immunity 40, 235–247, February 20, 2014 ª2014 Elsevier Inc.we studied effector OT-II T cell dynamics in the skin of animals
given 100 mg of OVA323 peptide and subjected to 10 hr of
continuous imaging. These analyses confirmed that antigen-
induced migration arrest was transient, with cells beginning to
regain motility 1–2 hr after peptide injection and nearing their
original speeds by 6–8 hr (Figure 2E and Movie S4). We also
examined the migration of individual T cells (Figure S3). Individ-
ual T cells rapidly arrested after peptide administration, but the
subsequent recovery period was heterogeneous, with some
cells regaining motility within 30 min and others remaining
arrested for several hours. A rare population of T cells never
regained motility during the imaging period. After an extended
arrest period induced by peptide injection, most T cells showed
a prolonged recovery, oscillating between periods of brief arrest
and motility, suggestive of additional TCR stimulation, before
regaining a migration pattern similar to what was observed in
the absence of antigen.
Ex vivo analysis of IFN-g production without restimulation
under the same experimental conditions showed an inverse rela-
tionship between migration and effector activity; T cells reached
a peak of IFN-g production by 2 hr after initial antigen contact
during which time they showed migration arrest; they then
ceased making cytokine as they regained motility over the next
several hours (Figure 2E). Given that the velocity change largely
reflected individual cells transiting between the arrested and
motile states (Figure S3), these data are consistent with T cells
making cytokine during prolonged contacts with APCs and
ending cytokine production as they transition back to the migra-
tory state.
Intact Antigen Presentation after the Regain of T Cell
Motility
This ‘‘single cycle’’ response of effector T cells in an inflamed
tissue was unexpected and led us to investigate the molecular
mechanisms underlying this behavior. Two major possibilities
were considered: first, the loss of displayed pMHC ligands and
the associated TCR ‘‘stop signal’’ (Dustin, 2004) and second, a
change in the response of the T cells to continued antigen
display. We examined the first possibility by using a new cohort
of adoptively transferred OT-II effector cells as a sensitive indica-
tor of residual dermal antigen display when the in situ cohort of
OT-II cells had regained motility several hours after antigenic
stimulation. If we observed migration arrest of this new OT-II
cohort but not of control effector T cells of a different specificity,
this would exclude loss of antigenic signal as the basis of the
termination of cytokine production and regain of migratory
behavior. A DTH response to KLH was induced as before and
the mice were injected with OVA323 peptide to induce synchro-
nized TCR activation. Nine hours after peptide injection, when
the initial cohort of endogenously primed OT-II cells had re-
gained motility, in vitro generated OT-II effector T cells and con-
trol p25 effector T cells recognizing the mycobacterial antigen,
antigen-85b (Ag85b), were labeled with different dyes and adop-
tively transferred into the OVA323-challenged or saline-treated
animals (Figure 3A). In the OVA peptide-injected recipients, the
in situ primed OT-II effector T cells had almost fully regained
motility and moved at nearly the same velocity as the control
transferred p25 T cells (Figures 3B and 3C). In clear contrast,
a large fraction of the newly transferred OT-II effector T cells
Figure 2. Synchronized Activation of Effector T Cells Reveals Inverse Correlation between Effector Function and Motility
(A) Schematic illustration of modified DTH system.
(B) Antigen-induced OT-II T cell arrest in response to different doses of OVA323 peptide. Each line represents the average normalized instantaneous velocity over
time from an individual animal treated at a given peptide dose. The velocity before OVA323 peptide administration is normalized to one. Data are compiled from
multiple experiments. See also Figures S2, S3, and Movie S3.
(C and D) Representative flow cytometry histograms (C) and quantification (D) of IFN-g production from OT-II T cells 2 hr after administration of different doses of
OVA323 peptide. Graph shows the percent OTII-T cells that are IFN-g+; mean ± SEM from at least three mice per group.
(E) OT-II T cell instantaneous velocity over time and the percent OT-II T cells that are IFN-g+ (mean ± SEM) before and after administration of 100 mg of OVA323. All
data are representative of three or more independent experiments.
See also Movie S4.
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OT-II cells transferred into animals without OVA323 peptide
injection, the migration-inhibited OT-II T cells that had recovered
motility at this time point in peptide-treated animals, or p25
control cells in the same tissue (Figures 3B–3D and Movie S5).These results indicated that dermal APCs still presented enough
antigen to mediate specific migration arrest even 12 hr after
peptide administration, raising the possibility that disso-
ciation of previously activated effector T cells from APCs and
cessation of cytokine production beginning a few hours afterImmunity 40, 235–247, February 20, 2014 ª2014 Elsevier Inc. 239
Figure 3. Antigen Presentation Persists after the Regain of T Cell Motility
(A) Schematic illustration of experimental protocol.
(B) Representative image from an intravital data set (left). Image was taken 12 hr after administration of 100 mg of OVA323. In vitro primed OT-II T cells and p25
T cells were labeled with CMTMR (red) and Cell Tracker blue (blue), respectively, and transferred 3 hr before image acquisition. Right panel shows the paths of
T cell migration over the duration of the movie.
(C and D) Quantification of mean velocity for endogenously primed OT-II T cells and in vitro generated OT-II T cells and p25 T cells with (C) or without (D) OVA323
administration. Horizontal lines indicate median value of the population. Data are representative of two independent experiments.
Scale bar represents 50 mm. See also Movie S5.
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to changes in the T cell response to an otherwise activating level
of presented antigen.
PD-1 Expression on T Cells Is Increased after
Antigen-Induced Arrest
Multiple T-cell-intrinsic processes could regulate the termination
of TCR signaling and subsequent disengagement from APCs.
The most direct mechanisms would involve antigen-induced
downmodulation of the TCR (Utzny et al., 2006; Valitutti et al.,
2010), the CD4 coreceptor (Schreiber et al., 2010), or other
receptors mediating cell adhesion or regulating chemokine
sensitivity. Alternatively, several T cell surface molecules have
been proposed to actively inhibit antigen-induced stopping
and promote T cell motility, including CTLA4 (Downey et al.,
2008; Schneider et al., 2006, 2008) and PD-1 (Fife et al., 2009;
Schreiber et al., 2010). The surface expression of both CTLA4
and PD-1 is increased upon TCR signaling, so both were candi-
dates for molecules that might contribute to time-dependent
desensitization and loss of TCR-induced migration arrest and
cytokine production. We therefore looked for changes in expres-
sion of various surface molecules on OT-II T cells after antigen-
induced arrest (Figure 4A). PD-1 but not CTLA4, Lag3, TCR,
CD28, the integrins LFA-1 and ICAM, or various chemokine
receptors showed substantial expression change within 3 hr of240 Immunity 40, 235–247, February 20, 2014 ª2014 Elsevier Inc.antigen-induced arrest. For PD-1, there was a significant mem-
brane increase in close kinetic correlation with the loss of migra-
tion arrest and effector activity (Figure 4B). Given that the PD-1
ligands PD-L1 and PD-L2 are well expressed on skin CD11c+
MHCII+ cells (Figure S4) and that these cells can serve as
APCs for effector T cells during DTH responses (Movie S6),
these results suggested the possibility that engagement of an
increasing pool of surface PD-1 might play a role in the disen-
gagement of T cells from APCs and the regain of motility that
begins a few hours after antigen activation in the skin.
Blockade of PD-L1 Slows T Cell Motility Recovery and
Prolongs Cytokine Production after Antigen-Induced
Arrest
To examine whether PD-1 played a role in regulation of T cell
effector behavior after acute antigen activation, we inhibited its
interaction with its ligands PD-L1 or PD-L2. Data were recorded
in each experimental animal from a single imaging field before
and then every hour after acute challenge with OVA323 for up
to 8 hr, allowing examination of the effects of antibody blockade
on motility while taking into account animal-to-animal variability
and effects of local differences in tissue structure and phase of
the DTH response. In control mice given isotype-matched anti-
body, the average velocity of the OT-II T cells had recovered to
the basal state by 6 hr after antigen-induced arrest (Figure 5A).
Figure 4. Expression of Surface Molecules on OT-II T Cells after OVA323 Administration
(A) Representative histogram of various surfacemolecules on OT-II T cells from at least three independent experiments. DTH ear skin was collected and digested
at the indicated time point after administration of 100 mg of OVA323 and cells were surface stained with the indicated antibodies. Intracellular staining was
performed for CTLA4.
(B) Themedian fluorescence intensity (MFI) of PD-1 staining was quantified before and after peptide administration. All valueswere normalized to the averageMFI
of the OVA(-) group, set as 100. p values, unpaired Student’s t test.
See also Figure S4 and Movie S6.
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Figure 5. Effect of Blocking Antibodies on
the Recovery of T Cell Motility after OVA323
Administration
(A–D) Representative time course of mean velocity
for OT-II T cells before and after administration of
100 mg of OVA323 in the presence of isotype anti-
body (A), anti-PD-L1 antibody (B), anti-PD-L2
antibody (C), or anti-CTL4 antibody (D). Themedian
value of the population before OVA323 adminis-
tration was set as one, and each dot indicates an
individual cell. Blue horizontal lines indicate the
ratio of mean velocity to initial velocity at the indi-
cated time point, and red dashed lines indicate
initial velocity. Data are generated from 30min data
sets beginning at each indicated time point. See
also Figure S5.
(E) Summary of the time course of T cell motility
change from data in (A)–(D). Each symbol indicates
the ratio of the mean velocity as in (A)–(D).
(F) Quantification of motility recovery for OT-II
T cells in the presence of different blocking anti-
bodies. Area under the curve in (E) was measured.
Each symbol indicates area under the curve for an
individual independent experiment (mean ± SEM).
(G and H) Comparison of mean velocity between
in vivo primed p25 T cells and OT-II T cells 8 hr after
OVA323 stimulation either with isotype antibody
treatment (G) or anti-PD-L1 antibody (H). Data
are representative of three or more independent
experiments.
p values, unpaired Student’s t test. n.s. indicates
not significant. See also Figure S6 and Movie S6.
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tion of antigen-induced T cell arrest, with the average mean
velocity remaining below baseline for the 6 hr duration of the
imaging session (Figure 5B). There was no effect of anti-PD-L1
antibody on the velocity of effector T cells in the absence of
antigen-specific engagement (data not shown). Administration
of anti-PD-L2 antibody (Figure 5C) or anti-CTLA4 antibody (Fig-
ure 5D) did not result in the same change in motility reacquisition
by the T cells (summarized in Figure 5E). Although a trend toward242 Immunity 40, 235–247, February 20, 2014 ª2014 Elsevier Inc.slower recovery of motility was observed
with anti-CTLA4 treatment, careful anal-
ysis of the area under the curve for the
results shown in Figure 5E revealed that
only anti-PD-L1 treatment had a signifi-
cant effect on changes in motility after
antigen-induced arrest (Figure 5F). To
control for T-cell-extrinsic effects of anti-
PD-L1 treatment, we performed additional
experiments with control effector p25
T cells. Mice were transferred with both
OT-II-CFP T cells and p25-eGFP T cells
and then immunized with CFA containing
OVA323 and Ag85b peptides to generate
both types of effector T cells in situ. After
KLH challenge, both effector populations
were observed in the dermis and could
be discriminated based on their unique
fluorescent protein expression. Micewere treated with either anti-PD-L1 antibody or control isotype
antibody and then injected with OVA323. Antibody treatment
did not affect initial antigen-induced arrest (Figure S5). At 8 hr
after OVA323 injection in animals given control antibody, the
average velocity of OT-II-CFP T cells was the same as in p25-
eGFP-T cells, whereas in mice treated with anti-PD-L1 antibody,
the average velocity of OT-II-CFP T cells was significantly lower
than that of the p25-eGFP T cells (Figures 5G and 5H and Movie
S6), confirming that blockade of PD-L1 signaling caused a delay
Figure 6. PD-L1 Blockade Prolongs Effector
Function of OT-II T Cells after Antigen-
Induced Arrest
Representative contour plots (A) and quantification
(B) for IFN-g production from OT-II T cells in the
presence and absence of anti-PD-L1 antibody. DTH
was induced in primedmice and the animals treated
with isotype control or anti-PD-L1 blocking anti-
body prior to administration of 100 mg OVA323. Skin
cells were collected 3 hr (B) or 8 hr (A and C) after
OVA323 administration and intracellular staining for
IFN-g was performed. Each symbol in (B) and (C)
indicates the result from an individual mouse. Data
are representative of three or more independent
experiments. p values, unpaired Student’s t test.
n.s. indicates not significant.
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tions, without affecting the velocity of bystander populations
of effector T cells that were not engaged with APCs. We
also examined the effect of anti-PD-L1 treatment on T cell
dynamics at 48 hr after rechallenge with OVA protein. Consistent
with our findings via systemic peptide injection, we observed
decreased T cell motility and displacement after PD-L1 blockade
(Figure S6).
Together, these data suggest that PD-L1 signaling through
PD-1 on T cells can actively suppress antigen-driven T cell
arrest. Given our previous observations on the anticorrelation
of effector T cell motility and cytokine production, we hypothe-
sized that PD-1 engagement with PD-L1 would also affect the
temporal pattern of T cell effector function elicited by antigen
stimulation. IFN-g production from OT-II T cells after activation
by OVA323 peptide injection was examined with or without
anti-PD-L1 antibody administration. At 3 hr after OVA323 injec-
tion, close to the normal peak of the cytokine response, there
was no significant difference in the percentage of IFN-g-
producing OT-II T cells between isotype control-treated mice
and anti-PD-L1 antibody-treated mice (Figure 6B). However,
8 hr after OVA323 injection when the cells had usually regained
full motility and largely ceased induced cytokine production,
the percentage of IFN-g-producing cells was significantly higher
in anti-PD-L1 antibody-treatedmice than in control mice (Figures
6A and 6C), in accord with the accompanying delay in return to
the motile state (Figure 5B). Thus, PD-1 ligation plays an impor-
tant role in regulating the temporal evolution of both postactiva-
tion T cell migration dynamics and effector activity.
DISCUSSION
Useful adaptive immune T cell responses in tissues involve the
emigration of activated lymphocytes from the vasculature acrossImmunity 40, 235–247inflamed endothelium into the tissue
space. There these effector T cells migrate
in search of cells displaying processed
antigen in the context of MHCI or MHCII
molecules which, when found, allow
T cells to engage in host defense through
activation of specific effector programs.
The ensuing response must be robustenough to clear an invading pathogen but sufficiently restrained
so as to prevent excessive tissue damage. To explore how
effector T cell activity is controlled dynamically at sites of inflam-
mation, we established a DTHmodel in which very tight temporal
control of initial antigen recognition can be used to investigate
the temporal connections between T cell migration, interaction
with APCs, and effector activity.
Consistent with our prior observations (Egen et al., 2011), we
found that T cells rapidly arrest migration in response to antigen
challenge, an event tightly linked to effector cytokine production.
However, by 2–3 hr after initiation of TCR signaling, effector cells
exited their arrested state and began to migrate in the tissue
while ceasing cytokine production. This ‘‘single cycle’’ response
behavior occurred even though pMHC ligand density in the
tissue was sufficient to cause antigen-specific T cell stopping.
Analysis of negative regulatory pathways linked to TCR signaling
revealed a major, though not exclusive, role for PD-1 interaction
with APC-expressed PD-L1 in actively terminating antigen-
induced T cell arrest on APCs and limiting the duration of cyto-
kine production.
The effect of antigen recognition on T cell motility has been
previously examined in vitro and in vivo via various imaging
modalities. In vitro, TCR engagement by strong agonist pMHC
ligands at high densities induces a stop signal, with the T cell
in tight synaptic connection with the APC membrane (Dustin,
2004; Negulescu et al., 1996). Intravital dynamic imaging first
done in a rat experimental allergic encephalomyelitis model
has shown that 40% of transferred myelin basic protein-specific
effector T cells become immobile within the central nervous sys-
tem where their specific antigen exists, whereas almost all cells
with an irrelevant TCR migrated vigorously unless their antigen
was administered systemically (Kawakami et al., 2005). In
several other models, the majority of specific but not unspecific
CD4+ or CD8+ effector T cells in tissues or secondary lymphoid, February 20, 2014 ª2014 Elsevier Inc. 243
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of cognate antigen (Azar et al., 2010; Filipe-Santos et al., 2009;
Waite et al., 2011), and a similar pattern of TCR-induced migra-
tion arrest on strong ligands is seen among thymocytes (Bhakta
et al., 2005). In a more limited number of imaging studies, the
presence of cognate antigen does not result in a statistically
significant change in mean velocity of the antigen-specific
population (Filipe-Santos et al., 2009; Kim et al., 2009; Schaeffer
et al., 2009), although biological responses of these cells could
be measured. This led to the interpretation that transient contact
between the T cell and APC is adequate to drive full activation.
However, our study in a BCG liver granuloma model has shown
clearly that there is a close match in frequency between fully
arrested T cells and cytokine-producing T cells in the lesion
and that such cells represent only 5%–10% of the population
(Egen et al., 2011). Linkage of migration arrest and function
could be missed in analyses reporting ‘‘multi-hit’’ activation of
continuously migrating T cells when looking only at mean veloc-
ity metrics under conditions in which only a small fraction of
effectors at any moment were engaged in stopping behavior
and response.
This issue of whether T cells respond only when arrested on
APCsorwhile still migrating is of critical importance in developing
an understanding of the range over which cytokines might
mediate their effects in vivo. Although diffusion or bulk flow in
tissue fluid can in principle spread the signal from a cytokine
secreted by an activated, arrested effector cell (Mu¨ller et al.,
2012), migrating cells would clearly have an advantage in distrib-
uting such mediators widely in the tissue. This could be either
beneficial in limiting infectious spread or detrimental by produc-
ing tissue damage at sites distant from foci of infection that
require control. The data in the present report are consistent
with our findings in the granuloma model (Egen et al., 2011),
indicating that effector cells interacting with strong foreign
antigens undergo activation while tightly associated with APCs
and rapidly cease cytokine production and secretion once TCR
signaling wanes and contact is lost as migration resumes. Such
findings point to amodel of host defense inwhich locally secreted
rather than widely distributed cytokines play a predominant role.
This does not mean that the effect of a secreted cytokine is
limited to just the APCs conjugated with the arrested and acti-
vated T cells. IFN-g effects can be measured 80–100 mm from
an arrested and activated effector T cell (Mu¨ller et al., 2012).
This makes biological sense, because the cells in the immediate
vicinity of the APCs are the most likely to become infected if
microbe control is incomplete and therefore raising their resis-
tance to productive infection is a useful host defense strategy.
The upregulation of negative feedback regulators of TCR
signaling, especially PD-1, appeared to play the major role in
causing strongly arrested and activated T cells to regain motility
and cease cytokine production within a few hours of initial anti-
gen contact. Our findings are consistent with previous imaging
studies showing that PD-1 interaction with its ligands on APC
can limit the capacity of antigen to induce T cell migration arrest
and response (Fife et al., 2009) and are further supported by the
recent demonstration that PD-1 interactions can inhibit proximal
TCR signaling and thus limit the TCR-induced stop signal (Yoko-
suka et al., 2012). These data stand in contrast to a recent report
that PD-1 promotes migration arrest and effector function of244 Immunity 40, 235–247, February 20, 2014 ª2014 Elsevier Inc.splenic CD8+ T cells in a viral infection model (Zinselmeyer
et al., 2013); the basis for this difference in findings remains to
be determined. We also observed a trend toward a modest
decrease in the rate at which T cells regain motility after antigen
engagement after blockade of CTLA-4, although these findings
were not statistically significant. Nevertheless, a role for CTLA4
in reversing antigen-induced migration arrest of T cells has
been described in other circumstances (Downey et al., 2008;
Schneider et al., 2006, 2008) and given its endosomal localiza-
tion and TCR signaling-induced stabilization on the cell surface
(Egen and Allison, 2002; Linsley et al., 1996), it is tempting to
speculate that CTLA-4 may also function to sense the extent of
antigen engagement and modulate the duration of T cell con-
tacts with APCs.
At first glance, it seems counterintuitive that activated
effector T cells would cut short their response to antigen while
the latter persists in amounts adequate for effective stimulation
of newly arriving T cells of the same specificity. However, there
are several reasons why adaptively decreasing T cell antigen
sensitivity could be beneficial to immune responses. Regulatory
programs that actively promote disengagement of T cells from
APCs may prevent T cells from being trapped around inflamed
venules on the first antigen-bearing APC they encounter and
thereby promote the migration of T cells deeper into inflamed
tissue. In addition, general considerations of homeostasis as
well as explicit modeling have both suggested that the immune
system must find a careful balance between effective host
defense and the disruption of tissue integrity resulting from
the toxic effects of mediators such as cytokines, enzymes,
and reactive oxygen species (Grossman and Paul, 1992; Segel
and Bar-Or, 1999). Regulatory mechanisms that rapidly tune
down T cell antigen sensitivity to a point that precludes pro-
longed responses to the antigen density that first evoked the
response may provide one solution to this problem. Of course,
local desensitization of T cell activation thresholds could also
give pathogens a respite from attack if mechanisms do not
exist to maintain the T cell response in the face of continuing
infection. We propose that rapid antigen-driven desensitization
of T cells at the site of infection combined with a continuous
influx of newly generated effector T cells capable of delivering
a transient burst of activity allows for rapidly tuning the potency
of T cell responses in coordination with fluctuations in antigen
display. If antigen presentation is increasing, T cells at the
site of infection will be able to respond even with the sensitivity
loss that has occurred. If the antigen amount is stable or falling,
however, T cells already at the site of infection will cease to
participate in the response and continued effector activity will
be dependent on newly arriving effector T cells coming from
stem cell-like central memory cells (Gattinoni et al., 2011) and
capable of being activated by this lower amount of antigen.
These cells, produced within draining lymphoid organs, will
be activated upon arrival in the infected tissue only to the
extent that they are required to drive down pathogen load
and no more as a result of the same desensitization mecha-
nism, thus maximizing tissue viability while effectively defend-
ing the host. Seen in this framework, the feedback-controlled,
time-limited activity of effector T cells we document here pro-
vides insights into how the immune system balances the com-
peting requirements of host defense and tissue homeostasis.
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Mice
C57BL/6 OT-II TCR transgenic RAG1-deficient mice (Barnden et al., 1998) and
CD11c-YFP mice (Lindquist et al., 2004) were from Taconic Laboratories.
C57BL/6 p25 TCR transgenic RAG1-deficient animals were kindly provided
by J. Ernst (New York University School of Medicine, New York) (Wolf et al.,
2008). Albino C57BL/6-Tyrc-2J/c-2J mice and C57BL/6 ubiquitously expressing
eGFP or dsRed (Schaefer et al., 2001; Vintersten et al., 2004) were from
Jackson Laboratories. All mice were maintained in specific-pathogen-free
conditions at an Association for Assessment and Accreditation of Laboratory
Animal Care-accredited animal facility at the NIAID. All procedures were
approved by the NIAID Animal Care and Use Committee (National Institutes
of Health, Bethesda, MD).
DTH
Recipient mice were transferred with 2 3 104 T cells from donor mice by i.v.
injection. The recipient mice were then immunized with 100 ml of emulsion of
complete Freund’s adjuvant plus 50 mg KLH and 25 mg ovalbumin 323-339
peptide (OT-II) or Ag85b 240-254 peptide (p25) at the base of the tail the
next day. Seven days after the immunization, ear skin was challenged i.d.
with 20 mg KLH and/or OVA. Intravital imaging or flow cytometry analysis
was performed 48–72 hr after the challenge.
Blocking Antibodies
Rat IgG, anti-PD-L1 (10F.9G2), anti-CTLA4 (UC10-4F10-11) (all fromBioXCell),
and anti-PD-L2 (3.2) (kindly provided by G.J. Freeman, Dana-Farber Cancer
Institute, Boston, MA), were injected intravenously at 300 mg/mouse 1 day
and 1 hr before OVA peptide injection.
In Vitro T Cell Stimulation and Adoptive Transfer
For in vitro generated effector T cells, lymph nodes from TCR transgenic
mice were disrupted by passage through a 70 mm cell strainer (BD Biosci-
ences). 1 3 106 cells were stimulated with 1 3 107 mitomycin C-treated
C57BL/6 splenocytes in complete RPMI 1640 (10% FCS, 2 mM L-glutamine,
50 mM 2-mercaptoethanol, and penicillin plus streptomycin) plus 2 mM oval-
bumin 323-339 peptide (OT-II) or Ag85b 240-254 peptide (p25) in each well
of a 24-well plate. Two days after the stimulation, cells were expanded
in the presence of 20 U/ml recombinant human IL-2 (R&D Systems) and
used for experiments 6–7 days after activation. In vitro generated effector
T cells were labeled with 1 mM CMTPX or 100 mM cell tracker blue for
15 min at 37C in HBSS or 10 mM CMTMR (Invitrogen) for 15 min at 37C
in complete RPMI. 0.5–1 3 107 of each cell type was injected i.v. into recip-
ient animals.
Cell Isolation and Flow Cytometry
For skin lymphocyte isolation, ear skin was cut and separated from the carti-
lage. The separated ears were put into RPMI+1% fetal calf serum containing
0.33mg/ml of Liberase TL (Roche) and 0.05%DNase I (Boehringer Mannheim)
for 1 hr at 37C. After the incubation, the tissue was disrupted by passage
through a 70 mm cell strainer. Cell suspensions were washed and stained
with respective antibodies. For analysis of intracellular cytokine production,
cell suspensions were obtained in the same manner except that 10 mg/ml of
Brefeldine A (BFA) (Sigma) was included in the digest buffer and subsequent
steps were performed in the presence of 5 mg/ml BFA. Cells were surface
stained with anti-CD4 eFluor450 (Clone RM4-5), anti-PD-1 PeCy7 (Clone
29F.1A12) (Biolegend), anti-Lag3 PE (Clone eBioC9B7W), anti-Va2-TCR PE
(Clone B20.1), anti-CD3 PeCy7 (Clone 145-2C11), anti-ICAM-1 alexa700
(Clone YN1/1.7.4), anti-LFA-1 PE (Clone M17/4), anti-CD28 PE (Clone
37.51), anti-PD-L1 APC (Clone 10F.9G2), anti-CXCR3 PE (Clone CXCR3-
173), anti-CCR4 PeCy7 (Clone 2G12), and anti-Vb11 biotin (Clone RR3-15).
Cells were fixed with Cytofix buffer, permeabilized with Perm/Wash buffer
(BD Biosciences), and stained with anti-IFN-g Alexa Fluor 647 (Clone
XMG1.2) or anti-CTLA4 (Clone UC10-4B9). eGFP was detected in the FITC
channel and isotype controls were used to determine background signals
for intracellular stains. Flow cytometric data were collected on an LSR II
(BD Biosciences) and analyzed with FlowJo software (TreeStar).Intravital Multiphoton Microscopy
Mice were anesthetized and prepared for intravital 2P imaging. In brief, the
mouse was anesthetized with isoflurane and placed on a custom-designed
stage in a heat box. Ear skin was wet with a few drops of PBS and gently
placed onto a coverslip and covered with a tape. For acute injection of peptide
antigens during imaging, a catheter was placed into the tail vein via a 30GA
needle attached to PE-10 tubing (Becton Dickinson) and secured with Dura-
pore Tape (Fischer Scientific). Images were acquired on an LSM 510 NLO
multiphoton imaging system (Carl Zeiss Microimaging) or LSM 710 NLOmulti-
photon imaging system (Carl Zeiss Microimaging), typically 10 z planes
spaced 3 mm apart every 45 s. Fluorescence excitation was provided by a
Chameleon Ti:Sapphire laser (Coherent). eGFP and CFP were excited at
920 nm or 900 nm and CMFDA and CMTPX were excited at 840 nm. Raw im-
aging data were processed with Imaris (Biplane). Automatic object tracking via
Imaris Spots was aided with manual corrections to retrieve cell spatial coordi-
nates over time and the resulting data were analyzed inMATLAB (MathWorks).
AfterEffects (Adobe) or ImageJ software (National Institute of Health) was used
to produce video clips.
Statistical Analysis
Data were analyzed with GraphPad Prism5 software. p values were calculated
by the unpaired Student’s t test and values of 0.05 or less were considered
significant.
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